OPTIMIZING PRIMARY STROKE PREVENTION (STOP II)

优化中风初级预防（STOP II）

• 批准号: 7376170
• 负责人: CATERINA MINNITI
• 金额: $ 1.19万
• 依托单位: CHILDREN'S RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376170
• 关键词: OPTIMIZING; PRIMARY; STROKE; PREVENTION; STOP

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The proposed study is a follow-up to the Stroke Prevention Trial in Sickle Cell Anemia (STOP). STOP showed that children at high risk for stroke, among those with sickle cell anemia (SCA), can be identified through screening with transcranial doppler (TCD) ultrasound and that periodic transfusion reduces annual stroke incidence in high-risk patients from 10% to less than 1%. This is the first treatment strategy that prevented primary strokes in a randomized trial in this disease. It provides an opportunity to reduce the human and financial cost of stroke in SCA. However, a number of important questions that STOP was not designed to address remain unanswered, including how long treatment must be continued. The importance of this trial is that it will produce reliable information that can be used by clinicians and parents in making difficult decisions regarding the risks and benefits of continued transfusion for stroke prevention.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构适用于该中心，这不一定是调查员的机构。拟议的研究是镰状细胞贫血（Stop）中预防中风试验的后续行动。停止表明，可以通过颅内多普勒（TCD）超声检查筛查镰状细胞贫血（SCA）的患者，在患有镰状细胞贫血（SCA）的孩子中，定期输血将高危患者的年度中风发生率从10％降低到小于1％。这是在该疾病的一项随机试验中阻止主要中风的第一种治疗策略。它提供了减少SCA中风的人类和经济成本的机会。但是，许多重要的问题并非旨在解决解决方案，尚未得到解决，包括必须继续治疗多长时间。该试验的重要性在于，它将产生可靠的信息，临床医生和父母可以对持续输血的风险和益处做出艰难的决策，以预防中风。